Sol Gel Technologies Ltd Cash Flow Conversion Efficiency
Sol Gel Technologies Ltd cash flow conversion efficiency. Based on the latest financial reports, Sol Gel Technologies Ltd (SLGL) has a cash flow conversion efficiency ratio of 0.045x as of December 2022. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($1.89 Million) by net assets ($42.21 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Sol Gel Technologies Ltd (2014–2025)
Cash flow conversion efficiency of Sol Gel Technologies Ltd from 2014 to 2025. This chart illustrates how Sol Gel Technologies Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Sol Gel Technologies Ltd (SLGL) stock price for real-time trading data and today's change.
Sol Gel Technologies Ltd Cash Flow Conversion Ratio Explained
Sol Gel Technologies Ltd cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Sol Gel Technologies Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Sol Gel Technologies Ltd ranked by their cash flow conversion efficiency. Also see SLGL market cap for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Xsolla SPAC 1 Class A Ordinary Shares
NASDAQ:XSLL
|
-0.001x |
|
Izmir Demir Celik Sanayi AS
IS:IZMDC
|
-0.076x |
|
OP Bancorp
NASDAQ:OPBK
|
0.105x |
|
Aprogen Healthcare & Games Inc
KQ:109960
|
0.002x |
|
Translational Development Acquisition Corp. Ordinary Shares
NASDAQ:TDAC
|
-0.002x |
|
Alta Equipment Group Inc
NYSE:ALTG
|
-0.735x |
|
RideNow Group, Inc.
NASDAQ:RDNW
|
0.000x |
|
Nanexa AB
ST:NANEXA
|
-0.073x |
Annual Cash Flow Conversion Efficiency for Sol Gel Technologies Ltd (2014–2025)
The table below shows the annual cash flow conversion efficiency of Sol Gel Technologies Ltd from 2014 to 2025. Review how much free cash does Sol Gel Technologies Ltd generate to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $22.81 Million | $322.00K | 0.014x | +102.93% |
| 2024-12-31 | $28.85 Million | $-13.89 Million | -0.481x | -4.93% |
| 2023-12-31 | $38.64 Million | $-17.73 Million | -0.459x | -104.21% |
| 2022-12-31 | $42.21 Million | $-9.48 Million | -0.225x | -62.40% |
| 2021-12-31 | $55.59 Million | $-7.69 Million | -0.138x | +72.13% |
| 2020-12-31 | $50.85 Million | $-25.24 Million | -0.496x | -15.75% |
| 2019-12-31 | $52.47 Million | $-22.50 Million | -0.429x | -16.79% |
| 2018-12-31 | $63.91 Million | $-23.47 Million | -0.367x | -180.33% |
| 2017-12-31 | $-52.70 Million | $-24.09 Million | 0.457x | -22.55% |
| 2016-12-31 | $-31.34 Million | $-18.50 Million | 0.590x | -15.49% |
| 2015-12-31 | $-11.52 Million | $-8.04 Million | 0.698x | -67.11% |
| 2014-12-31 | $-2.27 Million | $-4.83 Million | 2.123x | -- |
About Sol Gel Technologies Ltd
Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc., develops topical dermatological drugs for patients with severe skin conditions in Israel, China, Switzerland, Canada, the United States and internationally. The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treat… Read more